Amsterdam Scientists Just Destroyed The Breast Cancer Tumors In Only 11 Days Without Chemotherapy
When there is a study showing a possible cancer cure is a great day and Europe scientists might have discovered an amazing breakthrough for breast cancer. It is the most common cancer among women. 1 out of 8 American women have possibility of developing it during their life and this clinical trial might have discovered a new way so we can rid us of it forever.
It was a research that was presented by Professor Nigel Bundred. He showed his research at the European Breast Cancer Conference held in Amsterdam and he shared his discovery from testing the efficiency of few drugs: Lapatinib and Herceptin.
People use these drugs during the treatment against breast cancer, yet it is the first time they are combined together, used before the chemotherapy and surgery. They eliminated certain breast cancer in 11 days only.
It was funded by the Cancer Research UK and they wanted to use all these drugs so they can fight the HER2 protein known as the human epidermal growth factor receptor 2. This protein has an influence over the division and growth of cancer cell and has higher chances of returning than other cancer types.
This treatment is appealing because it can get rid of the chemotherapy procedure and even surgery in certain cases.
Results of the Study
257 women who had HER2 + breast cancer participated in the study. 130 women were separated in two groups – some of the women took Herceptin, some lapatinib. They were treated for a period of 11 days after their diagnosis and before their surgery. The third group received no drugs before surgery and they were the control group. They found out that the women who got Herceptin and lapatinib combination, actually did not have cancer cells remaining in just 14 days and some had drastically reduced tumors.
The group, who got just Herceptin, had 0% with no trace of the cancer cells just 3% showed a reduced tumor size. It is clear that the drugs combination has the biggest results against breast cancer cells; compared to if you use them separately.
The current problem is that you can license Herceptin only if you want to use it with chemotherapy together. However this study and the results might help for this to change.
Even though there is still a lot of work, this study represents a big step in the fighting of the worst disease.